Analyst picks & changes

Centocor Inc.


Cor Therapeutics Inc.


Dillon Read's King upgraded CNTO to "outperform" from "neutral" following the release of disappointing data from CORR's Phase III trial of its Integrelin


inhibitor in all comers

Read the full 367 word article

How to gain access

Continue reading with a
two-week free trial.